MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/26892820261461866

Медицинская библиотека · Palliative medicine reports · 2026

Study Protocol for Feasibility Randomized, Placebo-Controlled Trial of Efficacy of Midazolam as the Second-Line Treatment for Dyspnea in Patients with Advanced Cancer.

Miwa Satoru, Mori Masanori, Oyamada Shunsuke, Yamaguchi Takuhiro, Ariyoshi Keisuke, Matsuda Yoshinobu, Suzuki Kozue, Tasaki Junichi, Hatano Yutaka, Nishijima Kaoru, Aiki Sayo, Hagimoto Satoshi, Kuriyama Toshiyuki, Okuda Yuka, Tashiro Shimon, Matsumoto Yoshihisa, Hashimoto Hironobu, Kawaguchi Takashi, Ishiguro Hiroshi, Zenda Sadamoto, Matsuoka Hiromichi, Hui David, Morita Tatsuya, Yamaguchi Takashi

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Dyspnea is one of the most distressing symptoms in patients with advanced cancer. Although systemic opioids are recommended as first-line pharmacologic treatment, 30-50% of patients do not achieve adequate relief. Midazolam is often used for persistent dyspnea despite opioid administration; however, robust evidence supporting its efficacy as a second-line treatment remains limited.

OBJECTIVES

To evaluate the feasibility of a randomized controlled trial assessing the efficacy and safety of continuous subcutaneous midazolam infusion as second-line treatment for persistent dyspnea despite morphine administration in hospitalized patients with advanced cancer.

METHODS

A protocol for a multicenter, randomized, double-blind, placebo-controlled feasibility trial (J-SUPPORT2201/JORTC-PAL22) is described. The trial is being conducted at nine sites in Japan.

POPULATION: Participants are hospitalized adult patients with advanced cancer who are not receiving active anticancer treatment and who experience dyspnea at rest (Integrated Palliative Care Outcome Scale dyspnea score ≥2) despite continuous morphine infusion.

INTERVENTION/CONTROL: Protocol treatment includes standardized morphine escalation plus continuous subcutaneous infusion of midazolam (9 or 6 mg/day for vulnerable patients) or placebo for 24 hours.

MEASUREMENTS: The primary endpoint is feasibility, defined as completion of protocol treatment at 24 hours. Secondary endpoints include dyspnea intensity, anxiety, rescue morphine use, communication, adverse events, and 30-day survival.

CONCLUSIONS

This feasibility trial will provide methodological insights and preliminary clinical data regarding midazolam as a second-line option for persistent dyspnea despite morphine infusion in patients with advanced cancer and help design future confirmatory trials.

Для цитирования: Miwa Satoru, Mori Masanori, Oyamada Shunsuke, Yamaguchi Takuhiro, Ariyoshi Keisuke, Matsuda Yoshinobu, Suzuki Kozue, Tasaki Junichi, Hatano Yutaka, Nishijima Kaoru, Aiki Sayo, Hagimoto Satoshi, Kuriyama Toshiyuki, Okuda Yuka, Tashiro Shimon, Matsumoto Yoshihisa, Hashimoto Hironobu, Kawaguchi Takashi, Ishiguro Hiroshi, Zenda Sadamoto, Matsuoka Hiromichi, Hui David, Morita Tatsuya, Yamaguchi Takashi. Study Protocol for Feasibility Randomized, Placebo-Controlled Trial of Efficacy of Midazolam as the Second-Line Treatment for Dyspnea in Patients with Advanced Cancer.. Palliative medicine reports. 2026. DOI: 10.1177/26892820261461866.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.